- DehydraTECH™
drug delivery platform achieved a 319% higher CBD blood concentration
level at 60 minutes than the generic coconut oil formulation
- The
technology can be used on the nicotine market, the pharmaceutical market,
and the cannabinoid market
- No other
company in the world has a patent for improved delivery of all
non-psychoactive cannabinoids
- Partnership
with one of the world’s largest tobacco companies with up to $12 million
in Lexaria funding for clinical investigations and product development
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has
launched a revolutionary technology that accelerates intestinal absorption of
bioactive substances administered without the need for inhalational dosing,
co-administration with sweeteners or sugars, and other unhealthy practices. It
is applicable to absorption of cannabis and nicotine, among other bioactive
substances.
According to company data, DehydraTECH™ can be used
successfully in multiple industries, including the nicotine market (estimated
at approximately $746 billion), the pharmaceutical market (more than $68
billion), as well as the cannabinoid market (estimated at over $10.5 billion) (http://ibn.fm/NpNF4).
DehydraTECH™ is patented for all non-psychoactive
cannabinoids as well as for tetrahydrocannabinol (THC) and psychoactive
cannabinoids. The platform reduces the time of onset of THC by four times on
average (http://ibn.fm/NzcIR).
Lexaria is the only company in the world that holds patents
for oral delivery of all cannabinoids and nicotine. The company has been
awarded 16 patents in the United States and Australia and holds 60 globally
pending patents. Recently, Lexaria obtained two patents for treating certain
conditions including, but not limited to heart disease, neurological diseases
such as Alzheimer’s, Parkinson’s, schizophrenia, and others. The platform has
potential applications to treat the common form of dementia as well as other
nervous system diseases.
The company has developed its technology based on
recognition of the fact that inhalation of drugs into the lungs can be
dangerous. Edible ingestion enables much healthier and safer absorption. The
platform has also been proven to deliver up to 10 times more of active
ingredients than traditional edibles. DehydraTECH™ is the first platform that
makes it possible to avail many of the benefits of inhalation while greatly
reducing the risks.
Medical researchers have struggled to find ways to penetrate
the blood brain barrier effectively to transport beneficial drugs for many
years. This barrier exists to block toxic or otherwise dangerous substances
from entering the brain and is formed by layers of microvascular endothelial
cells inside blood vessels. Lexaria’s DehydraTECH™ drug delivery platform
brings beneficial drugs to the brain faster.
In June 2019, Lexaria completed a series of animal studies
using an enhanced formulation of its DehydraTECH™ technology. This series built
on the company’s original, independent, third-party laboratory in
vitro lab experiments began in 2015, which showed utilization of the
DehydraTECH™ drug delivery platform increased the absorption levels of
cannabidiol (CBD) in human intestinal cells by an impressive 499%. The results
of the studies showed delivery of 1,937% more CBD into animal brain tissue
after 8 hours using the enhanced DehydraTECH™ technology in comparison with
generic industry MCT coconut-oil formulations. Moreover, the animal
studies using the enhanced formulation showed an 811% increase of CBD delivery
into the blood in comparison with generic MCT coconut-oil formulations.
Additionally, Lexaria recently partnered with one of the
world’s largest tobacco companies, which is providing up to $12 million to fund
100% of Lexaria’s portion of the obligations for clinical investigations and
development of oral forms of nicotine delivery using the DehydraTECH™ drug
delivery platform (http://ibn.fm/JZBKX).
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
